Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial-Reference-Cited by-同舟云学术

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Published:2019-08 Issue:8 Volume:7 Page:606-617
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Mosenzon Ofri,Wiviott Stephen D,Cahn Avivit,Rozenberg Aliza,Yanuv Ilan,Goodrich Erica L,Murphy Sabina A,Heerspink Hiddo J L,Zelniker Thomas A,Dwyer Jamie P,Bhatt Deepak L,Leiter Lawrence A,McGuire Darren K,Wilding John P H,Kato Eri T,Gause-Nilsson Ingrid A M,Fredriksson Martin,Johansson Peter A,Langkilde Anna Maria,Sabatine Marc S,Raz Itamar

Funder

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. The effect of RAAS blockade on the progression of diabetic nephropathy;Roscioni;Nat Rev Nephrol,2014

2. Diabetic kidney disease: a clinical update from kidney disease: improving global outcomes;Molitch;Kidney Int,2015

3. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes;Schievink;Diabetes Obes Metab,2016

4. Temporal trends in the prevalence of diabetic kidney disease in the United States;de Boer;JAMA,2011

5. Kidney disease and increased mortality risk in type 2 diabetes;Afkarian;J Am Soc Nephrol,2013

Cited by 482 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk;The Lancet Regional Health - Europe;2024-03

2. Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity;Current Problems in Cardiology;2024-03

3. Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database;Diabetes, Obesity and Metabolism;2024-01-30

4. Treatment of type 2 diabetes;Die Diabetologie;2024-01-30

5. Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database;Cardiovascular Diabetology;2024-01-09